Business Context and Reporting Period
This Form 8-K was filed by Senseonics Holdings, Inc. on February 11, 2022. The report announces preliminary, unaudited financial results for the quarter and full year ended December 31, 2021, and provides a business outlook for 2022 following the U.S. Food and Drug Administration (FDA) approval of the Eversense E3 continuous glucose monitoring (CGM) system.
Key Financial Metrics
- Liquidity: As of December 31, 2021, the Company held approximately $182 million in cash, cash equivalents, and marketable securities.
- Revenue and Profit: The filing references preliminary results for Q4 and full-year 2021 but does not disclose specific revenue, profit, or margin figures within this text. These details are contained in the press release furnished as Exhibit 99.1.
- Debt: The filing text does not provide specific debt figures.
Material Changes and Operational Updates
- Regulatory Approval: The FDA approved the Eversense E3 CGM system for marketing in the United States, allowing for use for up to six months.
- Commercial Partnership: The Company continues its collaboration with Ascensia Diabetes Care Holdings (AG) for global distribution. Ascensia assumed full commercial responsibilities in the U.S. during 2021.
- Product Transition: The Company anticipates approximately 600 U.S. users and 2,600 European users upgrading from previous generations to the Eversense E3 system as it becomes commercially available.
Guidance, Outlook, and Risks
2022 Business Outlook:
- U.S. Launch: Commercialization of the Eversense E3 in the U.S. is expected to begin in the second quarter of 2022.
- European Launch: Launch in Europe is expected in the third quarter of 2022, subject to regulatory approval.
- Revenue Timing: First-quarter 2022 revenue is expected to be lower than fourth-quarter 2021 revenue due to current inventory levels of the 90-day and XL systems satisfying demand. Full-year 2022 revenue is expected to be significantly weighted toward the back half of the year.
- Geographic Mix: For the full year 2022, revenue outside the U.S. (OUS) is expected to exceed U.S. revenue.
Risks and Contingencies:
- Success of the Eversense E3 launch depends on growing the installed base, increasing patient and provider awareness, and expanding the network of authorized inserters.
- Timely establishment of favorable payor coverage, including transitioning from 90-day to six-month coverage, is critical.
- European revenues depend on Ascensia's sales capabilities and tender participation, particularly in Italy.
- Forward-looking statements are subject to uncertainties regarding the commercial launch, regulatory processes, and the ongoing impact of the COVID-19 pandemic.
Investor Verification Checklist
- Verify specific Q4 and full-year 2021 revenue and net loss figures in the press release (Exhibit 99.1) referenced in this filing.
- Confirm the exact timing of the Eversense E3 commercial launch in the U.S. (Q2 2022) and Europe (Q3 2022).
- Monitor the transition of payor coverage from 90-day to six-month reimbursement policies.
- Track the growth of the authorized inserter network, identified as a key strategic focus for adoption.
- Review the upcoming earnings release and investor call scheduled for March 1, 2022, for detailed commercialization strategies.